



## **AMENDMENTS**

## IN THE CLAIMS:

Please amend the claims as follows:

## 1-12. (Cancelled)

- 13. (Presently amended) A nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV adenovirus 5 sequence with exception of the E1 region.
- 14. (Presently amended) The A nucleic acid of Claim 13 comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248.
- 15. (Presently amended) A nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV adenovirus 5 sequence with exception of the L1 and E1 region.
- 16. (Presently amended) The A nucleic acid of Claim-15 comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817.

U.S. Serial No.: 09/923,270 Atty. Docket No.: 8484-101-999

17. (Presently amended) A composition comprising the nucleic acid of Claim 1, 2, 3, or 4 13, 14, 15, or 16, and an rAAV vector.

- 18. (Previously added) The composition of Claim 17, further comprising a cell.
- 19. (Previously added) The composition of Claim 18, wherein said cell is a mammalian cell.
- 20. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV adenovirus 5 sequence with exception of the E1 region;
  - b) inducing said cells to develop rAAV viral particles; and
  - c) isolating said rAAV viral particles.
- 21. (Presently amended) The A method of Claim 20, for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

<u>AAV viral particles</u>, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248;

- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

U.S. Serial No.: 09/923,270 Atty. Docket No.: 8484-101-999

22. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- exposing cells to a nucleic acid comprising an AAV helper virus sequence a) developing AAV viral particles, wherein said nucleic acid comprises the complete AAV adenovirus 5 sequence with exception of the L1 and the E1 region;
  - inducing said cells to develop rAAV viral particles; and b)
  - isolating said rAAV viral particles. c)
- 23. (Presently amended) The A method of Claim 22, for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- exposing cells to a nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817;
- inducing said cells to develop rAAV viral particles; and b) isolating said rAAV viral particles.

  - 24. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
  - a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence comprises the complete AAV adenovirus 5 sequence with exception of the E1 region, and (2) an rAAV vector;
    - inducing said cells to develop rAAV viral particles; and b)
    - isolating said rAAV viral particles. c)

U.S. Serial No.: 09/923,270 Atty. Docket No.: 8484-101-999

25. (Presently amended) The A method of Claim 24, for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248;
  - b) inducing said cells to develop rAAV viral particles; and
  - c) isolating said rAAV viral particles.
- 26. (Presently amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence comprises the complete AAV adenovirus 5 sequence with exception of the L1 and the E1 region;
  - b) inducing said cells to develop rAAV viral particles; and
  - c) isolating said rAAV viral particles.
- 27. (Presently amended) The A method of Claim 26, for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817;
  - b) inducing said cells to develop rAAV viral particles; and
  - c) isolating said rAAV viral particles.

